Literature DB >> 11058100

HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

B Bramlage1, E Luzi, F Eckstein.   

Abstract

A library of three synthetic ribozymes with randomized arms, targeting NUX, GUX and NXG triplets, respectively, were used to identify ribozyme-accessible sites on the HIV-1 LTR transcript comprising positions -533 to 386. Three cleavable sites were identified at positions 109, 115 and 161. Ribozymes were designed against these sites, either unmodified or with 2'-modifications and phosphorothioate groups, and their cleavage activities of the transcript were determined. Their biological activities were assessed in cell culture, using a HIV-1 model assay system where the LTR is a promoter for the expression of the reporter gene luciferase in a transient expression system. Intracellular efficiency of the ribozymes were determined by cotransfection of ribozyme and plasmid DNA, expressing the target RNA. Modified ribozymes, directed against positions 115 and 161, lowered the level of LTR mRNA in the cell resulting in inhibition of expression of the LTR-driven reporter gene luciferase of 87 and 61%, respectively. In the presence of Tat the inhibitions were 43 and 25%. The inactive variants of these ribozymes exhibited a similar inhibitory effect. RNase protection revealed a reduction of RNA which was somewhat stronger for the active than the inactive ribozymes, particularly for ribozyme 115. Unmodified ribozymes showed no inhibition in the cell. The third ribozyme, targeting a GUG-triplet at position 109, possessed only low cleavage activity in vitro and no inhibitory effect in cell culture.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058100      PMCID: PMC113160          DOI: 10.1093/nar/28.21.4059

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  61 in total

1.  HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation.

Authors:  M F Laspia; A P Rice; M B Mathews
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

2.  Selecting effective antisense reagents on combinatorial oligonucleotide arrays.

Authors:  N Milner; K U Mir; E M Southern
Journal:  Nat Biotechnol       Date:  1997-06       Impact factor: 54.908

3.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

4.  Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.

Authors:  C M Flory; P A Pavco; T C Jarvis; M E Lesch; F E Wincott; L Beigelman; S W Hunt; D J Schrier
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

5.  Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase.

Authors:  M Scherr; M Reed; C F Huang; A D Riggs; J J Rossi
Journal:  Mol Ther       Date:  2000-07       Impact factor: 11.454

6.  Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA.

Authors:  T C Jarvis; L J Alby; A A Beaudry; F E Wincott; L Beigelman; J A McSwiggen; N Usman; D T Stinchcomb
Journal:  RNA       Date:  1996-05       Impact factor: 4.942

7.  Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.

Authors:  L Beigelman; J A McSwiggen; K G Draper; C Gonzalez; K Jensen; A M Karpeisky; A S Modak; J Matulic-Adamic; A B DiRenzo; P Haeberli
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

8.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.

Authors:  B P Monia; J F Johnston; T Geiger; M Muller; D Fabbro
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

9.  Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via transfection or infection.

Authors:  P Artelt; C Morelle; M Ausmeier; M Fitzek; H Hauser
Journal:  Gene       Date:  1988-09-07       Impact factor: 3.688

10.  A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo.

Authors:  S P Lyngstadaas; S Risnes; B S Sproat; P S Thrane; H P Prydz
Journal:  EMBO J       Date:  1995-11-01       Impact factor: 11.598

View more
  4 in total

1.  Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

Authors:  A A Mir; T J Lockett; P Hendry
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

Authors:  Rosel Kretschmer-Kazemi Far; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

3.  Creating a ribonuclease T-tat that preferentially recognizes and hydrolyzes HIV-1 TAR RNA in vitro and in vivo.

Authors:  Chen Dow-Tien; Tsai Yuan-Jhih; Lin Alan
Journal:  Nucleic Acids Res       Date:  2007-12-17       Impact factor: 16.971

4.  A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.

Authors:  Robert J Scarborough; Michel V Lévesque; Etienne Boudrias-Dalle; Ian C Chute; Sylvanne M Daniels; Rodney J Ouellette; Jean-Pierre Perreault; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2014-07-29       Impact factor: 10.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.